OMB Control No. 0910-0500

Expiration Date: 9/30/2023

Paperwork Reduction Act Statement:  According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a valid OMB control number.  The valid OMB control number for this information collection is 0910-0500 and the expiration date is 09/30/2023.  The time required to complete this information collection is estimated to average 15 minutes, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

Send comments regarding this burden estimate or any other aspects of this collection of information, including suggestions for reducing burden, to PRAStaff@fda.hhs.gov.

The survey we are conducting is on behalf of the U.S. Food and Drug Administration (FDA).

COVID-19 Critical Care Drug Monitoring Survey Portal

**Follow-Up Outreach Email Template**

To Our Stakeholders on the Frontlines:

The Food and Drug Administration (FDA) plays a vital role in helping to address the Coronavirus Disease 2019 (COVID-19) pandemic and recognizes the critical role of your organization. Currently, FDA is working to identify and maintain a list of drugs essential for the care and management of hospitalized patients with COVID-19, particularly for ventilated patients in the intensive care units.

Input from you and organizations like yours help to identify drugs that may be at risk of a regional or national shortage. We request that you complete a brief survey that will be sent to you on a weekly basis. The information you provide to us will be used to help ensure these drugs remain available to meet the needs of our nation. We are requesting for you or another member of your organization to complete and return the survey as soon as possible. The initial survey will require that you register in FDA’s secure portal.

For any questions or if you would like to speak to someone at the FDA to assist in providing the information in the survey, please reach out to our Project Management Coordinator (Tomeka Arnett) at the following email: DMPD-COVID-19@fda.hhs.gov.

Thank you in advance for your input, your willingness to collaborate with FDA and join others in doing everything possible to continue to respond rapidly to the COVID-19 pandemic.

Sincerely,

**[NAME]**